Erika Paladini

Erika Paladini

Auto-generated profile, based on publicly available information

Erika Paladini

Clinical Pediatrics, Department of Molecular Medicine and Development University of Siena Siena Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2022 in Allergologia et Immunopathologia
Verified
Journal Article
Open access
PDF file
GLGiulia Lascialfari
Giulia Lascialfari
LSLucrezia Sarti
Lucrezia Sarti
SBsimona barni
simona barni
GLGiulia Liccioli
Giulia Liccioli
EPErika Paladini
Erika Paladini
Francesca MoriFrancesca Mori
Francesca Mori
Background: Chronic urticaria (CU), characterized by daily wheals and/or angioedema lasting more than 6 weeks, is a common skin disease. CU is classified as spontaneous or inducible. Because of Coronavirus Disease-19 (COVID-19) pandemic, face-to-face visits were reduced, and many centers started remote consultations to minimize hospital admissions and risk for viral diffusion. Telemedicine became a valuable tool for evaluating and monitoring patients with chronic diseases, such as CU. This study aims to evaluate the effectiveness of telemedicine as a means for the follow-up of patients with chronic spontaneous urticaria (CSU) during the COVID-19 pandemic. In particular, we collected data related to CSU evolution and treatment by remote consultation. Moreover, we specifically investigated the impact of SARS-CoV-2 infection or vaccination on CSU in relapsing or worsening of such a disease. Methods: The electronic charts were reviewed for patients diagnosed with CSU, who were referred to the allergy unit of Meyer Children’s Hospital, Florence. For each patient, a review of demographic characteristics, diagnostic workup, efficacy, and tolerability of the treatment was performed. Patients with a physical agent triggering CU were excluded from the study. Disease activity was monitored using the Urticaria Activity Score (UAS7). In addition, when the COVID-19 pandemic started, follow-up continued through telemedicine after an initial face-to-face visit when possible. Approximately 1 year after the diagnosis of CSU, patients were recontacted to investigate whether they had experienced a relapse or worsening of urticaria during a possible COVID-19 or immediately after receiving a COVID-19 vaccine. Results: From January 2020 to March 2021, 84 cases of CSU were identified, with 71 (84.5%) of these being evaluated via televisit (remote consultation). During the remote follow-up period, 38/71 (53.5%) patients who were evaluated via televisit recovered completely from CSU, while 24 (33.8%) made therapy adjustments, and 9 (12.7%) had to discontinue follow-up through remote visits and return to face-to-face visits. In February 2022, we recontacted the 71 patients with CSU, and 50 (70.4%) of them answered by phone call interview. Four (19.2%) of the 26 patients who had COVID-19 showed CSU relapse, while 1 (3.8%) had a CSU worsening. Instead, 1 (3.8%) patient of the 26 who were vaccinated had a relapse of CSU, and 1 (3.8%) had a worsening of CSU, both after the first dose. Conclusion: Our data showed that telemedicine can be an effective tool for the follow-up of patients with CSU. Moreover, COVID-19, as well as COVID-19 vaccination, may trigger CSU relapse or worsening, but both are unspecific triggers, and urticaria shows a very short duration in most cases.

19 June 2022 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
Francesca MoriFrancesca Mori
Francesca Mori
CFCamilla Fazi
Camilla Fazi
RPRiccardo Pertile
Riccardo Pertile
GLGiulia Liccioli
Giulia Liccioli
LSLucrezia Sarti
Lucrezia Sarti
CVClaudia Valleriani
Claudia Valleriani

16 June 2023 in Pediatric Allergy, Immunology, and Pulmonology
Verified
Journal Article
Closed access
Francesca MoriFrancesca Mori
Francesca Mori
Benedetta PessinaBenedetta Pessina
Benedetta Pessina
MGMattia Giovannini
Mattia Giovannini
GLGiulia Liccioli
Giulia Liccioli
LSLucrezia Sarti
Lucrezia Sarti
SBsimona barni
simona barni
Background: Oral immunotherapy (OIT) increases the threshold of reaction in children older than 4 years with food allergy. The risk for severe allergic reactions (ARs) during OIT has been reported in several studies, often in the presence of concomitant cofactors such as physical exercise, empty stomach, medications, poorly controlled asthma, menses, and alcohol consumption. Cases Presentation: We describe a case series of 5 scholar age patients undergoing OIT who showed ARs to a known, previously tolerated dose of allergen during permanent tooth eruption, in which other known cofactors were excluded. Conclusions: Patients may be exposed to cofactors due to behavioral habits not only in the second and third decades of life, but also in the first decade of life, due to the timing of mixed dentition. More studies are needed to estimate the frequency and entity of tooth eruption as cofactor, as well as to know the correct management of children undergoing dentition during OIT.

3 November 2026 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
GGGiacomo Gagliardi
Giacomo Gagliardi
LTLeonardo Tomei
Leonardo Tomei
GLGiulia Liccioli
Giulia Liccioli
SBsimona barni
simona barni
MGMattia Giovannini
Mattia Giovannini
Francesca MoriFrancesca Mori
Francesca Mori